Generation Bio(US:GBIO)2025-05-07 20:10Financial Performance - Cash balance as of March 31, 2025, was $157.6 million, down from $185.2 million as of December 31, 2024, expected to fund operations into the second half of 2027[6] - Net loss for Q1 2025 was $14.8 million, or $0.22 per share, compared to a net loss of $74.5 million, or $1.12 per share, in Q1 2024, indicating a substantial improvement[11] - Total operating expenses for Q1 2025 were $25.3 million, down from $81.7 million in Q1 2024, a decrease of 69.0%[16] - Loss on lease termination was $1.1 million in Q1 2025, significantly lower than $56.9 million in Q1 2024[11] Revenue and Expenses - Research and development (R&D) expenses for Q1 2025 were $15.4 million, compared to $14.3 million in Q1 2024, reflecting a year-over-year increase of 7.7%[7] - General and administrative (G&A) expenses decreased to $8.8 million in Q1 2025 from $10.4 million in Q1 2024, a reduction of 15.4%[7] - Collaboration revenue for Q1 2025 was $8.7 million, significantly higher than $4.1 million in Q1 2024, representing a 114.6% increase[16] Assets and Future Plans - Total assets as of March 31, 2025, were $201.3 million, down from $231.2 million as of December 31, 2024[14] - The company plans to announce the target and portfolio strategy for its lead ctLNP-siRNA program in mid-2025[4] - Generation Bio is focused on developing first-in-class treatments for T cell-driven autoimmune diseases using its innovative ctLNP technology[6]